The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Guest Editorial

ACS expands lung cancer screening eligibility to ages 50-80 with 20+ pack-years

Previous guideline was 55-74 with 30+ pack years

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

Lung Cancer Awareness Month kicked off this week, and this is a monumental one for us at the American Cancer Society.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Robert A. Smith, PhD
Senior vice president, Early Cancer Detection Science, American Cancer Society
William L. Dahut, MD
Chief scientific officer, American Cancer Society
Table of Contents

YOU MAY BE INTERESTED IN

Obituary

Harold Freeman, a surgeon who championed health equity, dies at 93
Freeman, the father of patient navigation, served as president of ACS and chair of the President’s Cancer Panel

Harold P. Freeman, a surgeon who started his career in Harlem, where, in addition to performing surgeries, he pioneered the system of patient navigation, and who studied health disparities and served as president of the American Cancer Society and chair of the President’s Cancer Panel, died on Aug. 11. He was 93.
By Paul Goldberg
Clinical Roundup

Ris-Rez reduced risk of death by 54% vs. topotecan in patients with relapsed SCLC, phase III trial in China finds

Hansoh Pharmaceutical Group announced positive overall survival data from ARTEMIS-008, its pivotal phase III trial in China, evaluating the B7-H3-targeted antibody-drug conjugate risvutatug rezetecan (Ris-Rez) versus topotecan in patients with relapsed small cell lung cancer whose disease progressed following platinum-based first-line therapy.
Clinical Roundup

Rybrevant + chemo delivers longest reported median OS in EGFR exon 20 insertion mutation-positive lung cancer

Patients with with advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations treated with intravenous Rybrevant (amivantamab-vmjw) plus carboplatin-pemetrexed chemotherapy achieved a median OS of nearly three years (34.3 months), compared with 27.9 months for chemotherapy alone, according to the final overall survival analysis of the phase III PAPILLON study. 
Byline
Robert A. Smith, PhD
Senior vice president, Early Cancer Detection Science, American Cancer Society
William L. Dahut, MD
Chief scientific officer, American Cancer Society
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account